Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Amer H. Zureikat

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7800-5464; OpenAlex author ID A5052559700, A5110939286, A5113185010, A5152864572, A5158356604. Sources: OpenAlex.

Their work

Papers
80 (first author 5, last author 13)
Trials
0
Grants
0
Labs led
2
Collaborators
147
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: 2 papers · 2015: 1 paper · 2016: 2 papers · 2017: 4 papers · 2018: 4 papers · 2019: 2 papers · 2020: 12 papers · 2021: 13 papers · 2022: 6 papers · 2023: 6 papers · 2024: 7 papers · 2025: 7 papers · 2026: 11 papers

Papers 50 of 80

  1. Pretreatment CA19-9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy. Co-author DOI 10.1002/jso.70179↗
  2. Cigarette smoking drives earlier development of pancreatic adenocarcinoma among carriers of hereditary pancreatic cancer susceptibility genes. Co-author DOI 10.1016/j.pan.2026.05.004↗
  3. Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium. Co-author DOI 10.1093/jnci/djag024↗
  4. Prediction of resection after preoperative FOLFIRINOX in patients with localized pancreatic adenocarcinoma: a Trans-Atlantic Pancreatic Surgery (TAPS) Consorti… Co-author DOI 10.1093/jnci/djag033↗
  5. Pancreatic Cancer Organoids Recapitulate Chemotherapy Response and Identify a Potent Cytotoxic T-Cell Population. Last author DOI 10.1158/1078-0432.ccr-25-1110↗
  6. KRAS Mutation Allele Frequency Dynamics in Plasma Extracellular Vesicles: Association with Survival in Localized Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18633-7↗
  7. Liquid Biopsy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. Co-author DOI 10.1245/s10434-026-20413-w↗
  8. ASO Visual Abstract: Liquid Biopsy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis. Co-author DOI 10.1245/s10434-026-20555-x↗
  9. Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancreatic Surgery Consorti… Co-author DOI 10.1245/s10434-026-20620-5↗
  10. ASO Visual Abstract: Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancre… Co-author DOI 10.1245/s10434-026-20742-w↗
  11. A Biomarker Panel for the Detection of Pancreatic Cancer. Co-author DOI 10.3390/cancers18091397↗
  12. Implications of an Isolated Positive Vascular Groove After Whipple for Pancreatic Adenocarcinoma: A Single Institution, Retrospective Analysis. Co-author DOI 10.1002/jso.70052↗
  13. Optimizing Perioperative Management of Pancreatic Ductal Adenocarcinoma: Insights Into Modified FOLFIRINOX Relative Dose Intensity and CA 19-9 Dynamics. Co-author DOI 10.1002/jso.70057↗
  14. Survival prediction for CA19-9 non-producers with resected pancreatic cancer. Co-author DOI 10.1016/j.hpb.2025.05.007↗
  15. Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical… Co-author DOI 10.1093/bjs/znaf011↗
  16. Combination therapy with immune agonists and senescence-inducing agents delivers promise for immunotherapeutic success in pancreatic cancer. First author DOI 10.1093/jleuko/qiae234↗
  17. Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: An American Mult… Co-author DOI 10.1245/s10434-025-16916-7↗
  18. ASO Visual Abstract: KRAS Mutation Allele Frequency Dynamics in Plasma Extracellular Vesicles: Associations with Survival in Localized Pancreatic Adenocarcinoma Co-author DOI 10.1245/s10434-025-18842-0↗
  19. Postoperative infectious complications worsen oncologic outcomes following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.27595↗
  20. Impact of Neoadjuvant Therapy on Oncological Outcomes of Patients With Distal Pancreatic Adenocarcinoma. Co-author DOI 10.1002/jso.27856↗
  21. Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: Trans-Atlantic Pancreatic Surg… Co-author DOI 10.1093/bjs/znae033↗
  22. Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study. Co-author DOI 10.1200/jco.23.01311↗
  23. Pancreatic Cancer Multidisciplinary Clinic is Associated with Improved Treatment and Elimination of Socioeconomic Disparities. Last author DOI 10.1245/s10434-023-14609-7↗
  24. Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRIN… Co-author DOI 10.1245/s10434-023-14680-0↗
  25. ASO Author Reflections: The Value of Serum CEA for Prognostication at Staging and Response Evaluation in Patients with Localized Pancreatic Adenocarcinoma and … Co-author DOI 10.1245/s10434-023-14815-3↗
  26. The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients. Co-author DOI 10.1016/j.hpb.2022.12.002↗
  27. No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.01.016↗
  28. Obesity Is Associated With Increased Risk for Adverse Postoperative Outcomes After Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jss.2022.11.050↗
  29. A Combined DNA/RNA-based Next-Generation Sequencing Platform to Improve the Classification of Pancreatic Cysts and Early Detection of Pancreatic Cancer Arising… Co-author DOI 10.1097/sla.0000000000005904↗
  30. Editorial on: Moving Beyond Anatomic Criteria for Resectability: Validation of the Anatomical and Biological Definitions of Borderline Resectable Pancreatic Ca… First author DOI 10.1245/s10434-023-13271-3↗
  31. Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer. Last author DOI 10.6004/jnccn.2023.7070↗
  32. Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer. Last author DOI 10.1001/jamanetworkopen.2022.18355↗
  33. Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict … Co-author DOI 10.1016/j.cgh.2020.11.041↗
  34. Advances in the Surgical Treatment of Pancreatic Cancer. Last author DOI 10.1016/j.path.2022.05.003↗
  35. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. Co-author DOI 10.1093/jnci/djac018↗
  36. Neoadjuvant therapy in pancreatic cancer: a review and update on recent trials. First author DOI 10.1097/mog.0000000000000874↗
  37. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. Co-author DOI 10.6004/jnccn.2022.7008↗
  38. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal… Co-author DOI 10.1002/jso.26267↗
  39. Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.26510↗
  40. Medicaid expansion and the management of pancreatic cancer. Co-author DOI 10.1002/jso.26515↗
  41. Safety and oncologic efficacy of robotic compared to open pancreaticoduodenectomy after neoadjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.1007/s00464-020-07638-w↗
  42. Impact of Resection Margin Status in Patients with Pancreatic Cancer: a National Cohort Study. Co-author DOI 10.1007/s11605-020-04870-6↗
  43. Perioperative and oncologic outcomes of open, laparoscopic, and robotic distal pancreatectomy for pancreatic adenocarcinoma. Co-author DOI 10.1007/s13304-020-00927-y↗
  44. Baseline Plasma Inflammatory Profile Is Associated With Response to Neoadjuvant Chemotherapy in Patients With Pancreatic Adenocarcinoma. Last author DOI 10.1097/cji.0000000000000370↗
  45. SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma. Co-author DOI 10.1111/cts.13029↗
  46. Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. Co-author DOI 10.1158/1078-0432.ccr-20-2475↗
  47. Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case-Control Matched Analysis. Last author DOI 10.1245/s10434-020-09391-9↗
  48. Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy. Co-author DOI 10.1245/s10434-020-09446-x↗
  49. A Pancreatic Cancer Multidisciplinary Clinic Eliminates Socioeconomic Disparities in Treatment and Improves Survival. Last author DOI 10.1245/s10434-021-09594-8↗
  50. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10175-y↗

Closest collaborators

The 25 strongest of 147 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alessandro Paniccia · 42 shared papers, 2020–2026 · strength 8.28
  2. Aatur Dilip Singhi · 27 shared papers, 2014–2026 · strength 3.71
  3. Herbert J. Zeh · 33 shared papers, 2012–2026 · strength 3.05
  4. Bas Groot Koerkamp · 13 shared papers, 2022–2026 · strength 2.85
  5. Nathan Bahary · 28 shared papers, 2013–2023 · strength 2.80
  6. Melissa Ellen Hogg · 26 shared papers, 2014–2026 · strength 2.67
  7. Ibrahim Nassour · 15 shared papers, 2020–2026 · strength 2.49
  8. Sebastiaan Ceuppens · 9 shared papers, 2025–2026 · strength 2.37
  9. Matthew H. G. Katz · 11 shared papers, 2022–2026 · strength 2.25
  10. Marc G. Besselink · 11 shared papers, 2022–2026 · strength 2.25
  11. Ching-Wei David Tzeng · 11 shared papers, 2022–2026 · strength 2.25
  12. Alice Chia-Chi Wei · 11 shared papers, 2022–2026 · strength 2.25
  13. Asmita Chopra · 12 shared papers, 2021–2026 · strength 2.24
  14. Brian A. Boone · 17 shared papers, 2013–2026 · strength 1.79
  15. Laura R. Prakash · 9 shared papers, 2022–2026 · strength 1.71
  16. Quisette P. Janssen · 8 shared papers, 2022–2026 · strength 1.45
  17. Caroline J. Rieser · 11 shared papers, 2018–2025 · strength 1.44
  18. Esther N. Dekker · 6 shared papers, 2024–2026 · strength 1.41
  19. Eileen Mary O'Reilly · 7 shared papers, 2022–2026 · strength 1.40
  20. Jiage Qian · 5 shared papers, 2025–2026 · strength 1.33
  21. Samer S. AlMasri · 8 shared papers, 2021–2024 · strength 1.33
  22. Michael T. Lotze · 10 shared papers, 2015–2026 · strength 1.24
  23. Randall E. Brand · 8 shared papers, 2018–2026 · strength 1.08
  24. Richard S. Hoehn · 7 shared papers, 2020–2024 · strength 1.00
  25. David L. Bartlett · 12 shared papers, 2012–2021 · strength 1.00

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.